Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy

New England Journal of Medicine

Volumn 365, Issue 24, 2011, Pages 2255-2267

  Boden, William E ^a   Probstfield, Jeffrey L ^b   Anderson, Todd ^c   Chaitman, Bernard R ^d   Desvignes Nickens, Patrice ^e   Koprowicz, Kent ^f   McBride, Ruth ^f   Teo, Koon ^g   Weintraub, William ^h  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF CALGARY   (Canada)

^d SAINT LOUIS UNIVERSITY   (United States)

^e NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^f Axio Research   (United States)

^g MCMASTER UNIVERSITY   (Canada)

^h CHRISTIANA CARE HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL; ANTILIPEMIC AGENT;

ACUTE CORONARY SYNDROME; ADD ON THERAPY; ADULT; ARTICLE; ATHEROSCLEROSIS; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CEREBRAL REVASCULARIZATION; COMBINATION CHEMOTHERAPY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEATH; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DYSLIPIDEMIA; FEMALE; FLUSHING; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HAZARD RATIO; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HOSPITALIZATION; HUMAN; ISCHEMIC HEART DISEASE; LIVER FUNCTION TEST; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; MYOPATHY; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RHABDOMYOLYSIS; RISK REDUCTION; SIDE EFFECT; AGED; BLOOD; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MUSCLE DISEASE; PATIENT COMPLIANCE; PROPORTIONAL HAZARDS MODEL; TREATMENT FAILURE;

AGED; ATHEROSCLEROSIS; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; KAPLAN-MEIER ESTIMATE; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MUSCULAR DISEASES; NIACIN; PROPORTIONAL HAZARDS MODELS; SIMVASTATIN; TREATMENT FAILURE; TRIGLYCERIDES;

EID: 84855171302     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1107579     Document Type: Article

References (22)

1. Tracking heart disease and stroke in Canada. Heart and Stroke Foundation of Canada, June 2009 (http://www.phac-aspc.gc.ca/publicat/2009/cvd-avc/pdf/cvd- avs-2009-eng.pdf).
2. Heart disease and stroke statistics - 2010 update: a report from the American Heart Association. Circulation 2010;121(7):e46-e215.
3. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670-81.
4. Castelli WP. Cholesterol and lipids in the risk of coronary artery disease - the Framingham Heart Study. Can J Cardiol 1988;4:Suppl:5A-10A.
5. Assmann G, Schulte H, von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk: the PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996;124:Suppl:S11-S20.
6. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360-81.
7. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245-55. (Pubitemid 17208898)
8. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999;341:410-8. (Pubitemid 29362514)
9. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583-92. (Pubitemid 33126837)
10. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504. [Erratum, N Engl J Med 2006;354: 778.] (Pubitemid 38477774)
11. Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007;357:1301-10. (Pubitemid 47481452)
12. Khot UN, Khot MB, Bajzer CT, et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003;290:898-904. (Pubitemid 37430461)
13. Nichols GA, Ambegaonkar BM, Sazonov V, Brown JP. Frequency of obtaining National Cholesterol Education Program Adult Treatment Panel III goals for all major serum lipoproteins after initiation of lipid altering therapy. Am J Cardiol 2009;104:1689-94.
14. The AIM-HIGH Investigators. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: rationale and study design. Am Heart J 2011;161(3):471.e2-477.e2.
15. Idem. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study participants. Am Heart J 2011;161:538-43.
16. Cashin-Hemphill L, Mack WJ, Pogoda JM, Sanmarco ME, Azen SP, Blankenhorn DH. Beneficial effects of colestipol-niacin on coronary atherosclerosis: a 4-year follow-up. JAMA 1990;264:3013-7.
17. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004;110:3512-7. [Errata, Circulation 2004;110:3615, 2005;111(24):e446.] (Pubitemid 39612564)
18. Villines TC, Stanek EJ, Devine PJ, et al. The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration. J Am Coll Cardiol 2010;55:2721-6.
19. Taylor AJ, Lee HJ, Sullenberger LE. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin 2006;22:2243-50. (Pubitemid 44789989)
20. Bruckert E, Labreuche J, Amarenco P. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis 2010;210:353-61.
21. Zhao X-Q, Dong L, Hatsukami T, et al. MR imaging of carotid plaque composition during lipid-lowering therapy: a prospective assessment of effect and time course. JACC Cardiovasc Imaging 2011;4:977-86.
22. Carlson LA. Nicotinic acid: its metabolism and its effects on plasma free fatty acids. In: Metabolic effects of nicotinic acid and its derivatives - proceedings of a workshop held in Films, Switzerland, 1970. Bern, Switzerland: Hans Huber, 1971:157-65.